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doi:10.1016/j.jmii.2011.01.007Background: Scrub typhus is an acute febrile disease for which synthetic tetracycline antibi-
otics are efficacious. However, no clinical studies have compared oral doxycycline with intra-
venous minocycline for treatment of scrub typhus.
Methods: We conducted a retrospective analysis in patients diagnosed with noncomplicated
scrub typhus by serologic or molecular methods from August 2001 to July 2007. We compared
the efficacy of intravenous minocycline with oral doxycycline for treatment of noncomplicated
scrub typhus in these patients.
Results: Forty seven cases receiving tetracycline antibiotics for the treatment of noncomplicated
scrub typhus were included. There was no statistically significant difference for the response rate
between the25cases receiving intravenousminocycline (96%) and the22cases receivingoral doxy-
cycline (91%) (pZ 0.909). Kaplan-Meier curve with a long-rank test for the time to defervescence
showed no statistically significant difference betweenminocycline therapy (mean 30 hours; range
4e124 hours) and doxycycline therapy (mean 32.4 hours; range 4e144 hours) (pZ 0.860). After
multivariate Cox regression models, the time to defervescence was only affected by Acute Physi-
ology and Chronic Health Evaluation II score (hazard ratio 0.868; pZ 0.016). Nearly all patients
(93.6%) became afebrile within 72 hours after use of tetracycline antibiotics. Prolonged hospital-
ization (> 7 days) was correlated with the timing to start tetracycline antibiotics after admission.
Conclusion: Both antibiotics have similar efficacy for the treatment of noncomplicated scrub
typhus. Nearly all cases responding to both antibiotics became afebrile within 3 days.
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34 C.-C. Tsai et al.Introduction Orientia tsutsugamushi serologic testing was performedScrub typhus is an acute febrile human disease caused by
Orientia tsutsugamushi that is transmitted to human by the
bite of an infected chigger. It is a common zoonotic disease
of rural Asia and western Pacific islands.1 In Taiwan, the
annual number of confirmed cases has increased from 39
cases in 1990 to 462 in 20052 because of the improvement of
diagnostic facilities, especially in eastern Taiwan where our
hospital is located. Clinical manifestations vary from mild
fever to multiple organ failure.3,4
Tetracycline compounds have been used for treatment
worldwide since their commercial introduction in 1953. The
development of synthetic antibiotics began with doxycy-
cline in 1967 and was followed by minocycline in 1972.5
Treatment with any tetracycline antibiotics for scrub
typhus typically results in rapid and complete recovery.6
Oral doxycycline is absorbed with a bioavailability of
more than 80%, mainly in the stomach, duodenum, and
jejunum. The oral form is more convenient to use than
intravenous form but needs 2e3 hours to reach peak con-
centrations.7e9 However, no clinical studies have compared
the efficacy for the treatment of noncomplicated scrub
typhus between oral doxycycline and intravenous minocy-
cline. The present study was undertaken with this aim.Methods
We performed a retrospective study at Buddhist Tzu Chi
General Hospital (Taiwan), a 900-bed tertiary care university
hospital and referral center. Hospitalized patients diagnosed
with scrub typhus by serologic or molecular methods were
enrolled. Patients complicated before tetracycline antibi-
otics therapy with acute renal or acute respiratory failure
were excluded. The definition of acute respiratory failure
was based on the sepsis-related organ failure assessment
score criteria in which 3 or 4 [PaO2/FiO2 (mmHg)< 200] is
defined as severe organ failure.10 Acute renal failure was
defined as a rapid 3-fold increase in serum creatinine,
decrease in glomerular filtration rate by 75%, or elevation of
serum creatine to more than 4 mg/dL according the Risk,
Injury, Failure, Loss, End stage classification of acute renal
failure published by the Acute Dialysis Quality Initiative
group in 2004.11 Patients’ medical data, including demo-
graphic characteristics, medical history, medications, labo-
ratory data, and outcome were collected for analysis.
In our hospital, thermometers were used to check body
temperature. Feverwas defined as a body temperaturemore
than 37.5C.When a patient’s body temperature returned to
normal after fever, itwas considered as defervescence. Time
to defervescence was defined as the duration between the
start of tetracycline antibiotic use and the resolution of
fever. Calculation of time to defervescencewas based on the
timing when the vital signs were checked. In the ordinary
ward of our hospital, the vital signs were checked every 8, 6,
or 4 hours. Fever could be detected before the moment
considered as the timing of defervescence and not detected
after thatmoment.When thepatient becamedefervescence
after use of tetracycline antibiotics, we considered
a response to the antibiotics had occurred.for the presence of IgM and IgG specific antibodies by use of
an indirect immunofluorescence assay.12 The O tsutsuga-
mushi antigens (Gilliam, Karp, and Kato strains) used were
cultured in L cells.13 IgM and IgG titers were determined in
acute- and convalescent-phase sera serially diluted 2-fold in
phosphate-buffered saline (PBS) froman initial 1:40 dilution.
The slides were rinsed and washed twice in PBS (pH 7.4)-
containing 0.05% Tween 20 (PBST) for 10 minutes. Fluores-
cein-conjugated goat anti-human IgM and IgG (Zymed,
SanFrancisco, CA, USA) was used at the appropriate dilutions
as the secondary antibody. After incubation for 30 minutes,
the slides were rinsed and washed twice with PBST. The
slides were mounted with mounting fluid (Chemicon, San
Diego, CA, USA) under coverslips and observed using an
ultraviolet epifluorescence microscope (Nikon, Tokyo,
Japan). Sera found positive (IgM> 1:80 or a 4-fold increase in
IgG titer in convalescent phase) were titrated to the
endpoint.
Peripheral blood mononuclear cells were extracted from
heparinized human blood samples by Ficoll/Hypaque
density-gradient centrifugation. The genomic DNA of O
tsutsugamushi was extracted by using the QIAamp Blood
Mini Kit (QIAGEN, Valencia, CA, USA) following the manu-
facturer’s protocols. O tsutsugamushi infection was diag-
nosed if the tested specimen was positive for the gene
encoding the 56-kDa protein by nested polymerase chain
reaction (PCR).14 Target DNA was amplified in a mixture
(total volume, 50 mL) containing 1.5 mM MgCl2, 50 mM KCl,
10 mM Tris-HCl (pH 8.3), 0.001% gelatin, 100 mM dNTPs,
0.2 mM primers, 1.25 U of FastStar Taq polymerase (Roche
Diagnostics, Mannheim, Germany) and 5 mL of template
DNA. The reaction was performed in 40 cycles of 94C for 30
seconds, 57C for 30 seconds, and 72C for 60 seconds in
a PTC-100 thermal cycler (MJ Research, Waltham, MA,
USA). The final cycle was followed by an extension step at
72C for 10 minutes. The size of the PCR-amplified products
was determined under ultraviolet light following ethidium
bromide staining.
SPSS 11.5 for MS Windows (SPSS Inc., Chicago, IL, USA)
software was used for the statistical analysis. Pearson’s
Chi-squared or Fisher’s exact test was used to examine
nominal data and unpaired Student’s t test was used for
continuous data. All tests were two-sided and a p value of
0.05 or less was considered significant. Time to deferves-
cence was compared by Kaplan-Meier survival methods.Results
Diagnosis of scrub typhus was confirmed by serology or
molecular methods from August 2001 to July 2007 in 62
patients treated by tetracycline antibiotics. Of these, one
patient received minocycline and levofloxacin simulta-
neously, and seven patients received oral minocycline. They
were excluded from this study. Seven of the remaining 54
patients had acute renal or acute respiratory failure before
usage of tetracycline antibiotics and were excluded. The
remaining 47 patients were included for this study. Twenty-
five cases received intravenous minocycline (Lederle paren-
terals, Carolina, USA) and 22 cases received oral doxycycline
(China Chemical & Pharmaceutical, Taipei, Taiwan). In the 25
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diagnosed with scrub typhus by the molecular method, 3 by
the serologic method, and 6 by both methods. In the other
group, 12 patients were diagnosed with scrub typhus by the
molecular method, 7 by the serologic method, and 3 by both
methods. The dosage of intravenous minocycline or oral
doxycycline was 100 mg every 12 hours. There were no
statistically significant difference between both groups in
demographic, clinical, and laboratory data (Table 1).
Both antibiotic regimens were highly effective for scrub
typhus. One patient did not respond to intravenous mino-
cycline and two patients did not respond to oral doxycy-
cline. They all responded to levofloxacin. The response rate
was more than 90% in both groups and there was no
statistically significant difference between two groups (96%
for minocycline vs. 91% for doxycycline; pZ 0.909). In the
intravenous minocycline-treated group, the mean time to
defervescence was 30.7 hours (range 4e124 hours). The
time in the oral doxycycline-treated group was 32.4 hours
(range 4e144 hours). Kaplan-Meier curves with a log-rank
test for the time to defervescence showed no statisticallyTable 1 Demographic and clinical characteristics of the patients
treatment of noncomplicated scrub typhusa
Characteristics Treatment
Intravenou
Demographics
Age, yr 47.9 21.0
No. of men/women 11/14
Duration of symptoms before use of tetracycline
antibiotics, d
8.4 4.5
Timing of starting tetracycline antibiotics after
admission, d
2.2 2.2
Underlying disease
Hypertension 2 (8)
Chronic hepatitis B or C 3 (12)
Diabetes mellitus 2 (8)
No underlying disease 17 (68)
Clinical symptoms and signs
Maximum body temperature, C 39.4 0.8
Fever 25 (100)
Relative bradycardia 16 (64)
Eschar 16 (64)
Skin rash 7 (28)
Headache 12 (48)
APACHE II score 5.7 3.3
Laboratory
WBC count,103/mL 6.7 2.0
Hemoglobin level, g/dL 12.8 1.3
Platelet count,103/mL 163.2 99
Alanine aminotransferase level, IU/L 93.7 52.4
Aspartate aminotransferase, IU/L 106.2 69
Blood urea nitrogen level, mg/dL 12.9 4.3
Serum creatine level, mg/dL 0.9 0.3
a Data are presented as mean  standard deviation or n (%).
APACHEZ Acute Physiology and Chronic Health Evaluation; WBCZwsignificant difference between both groups (pZ 0.860)
(Fig. 1). Nearly all patients (93.6%) became afebrile within
72 hours after use of tetracycline antibiotics. Acute Physi-
ology and Chronic Health Evaluation (APACHE) II score,
duration of symptoms before use of tetracycline antibi-
otics, timing to start tetracycline antibiotics after admis-
sion, and diabetes mellitus were considered as possible
confounding factors affecting time to defervescence. These
factors were checked by Cox regression models (Table 2).
APACHE II score was the most important factor to affect the
time to defervescence (hazard ratio 0.868; pZ 0.016).
Because nearly all patients became afebrile within 72
hours after use of appropriate antibiotics, more than
7-day hospitalization for scrub typhus was considered as
prolonged hospitalization. There were 36 patients with
hospitalization for 7 or less days and 11 patients with
hospitalization for more than 7 days. Timing to start tetr-
acycline antibiotics after admission was the most important
factor for prolonged hospitalization in the patients with
noncomplicated scrub typhus (1.3 0.5 days vs. 4.4 2.3
days, p< 0.001) (Table 3).receiving intravenous minocycline or oral doxycycline for the
p
s minocycline (nZ 25) Oral doxycycline (nZ 22)
57.1 12.6 0.081
14/8 0.906
6.5 3.0 0.107
1.8 1.1 0.465
4 (18) 0.398
1 (5) 0.611
0 (0) 0.491
17 (77) 0.702
39.1 0.8 0.140
22 (100) d
18 (82) 0.300
14 (64) 1.000
5 (23) 0.937
13 (59) 0.640
5.6 3.3 0.964
7.9 3.4 0.156
13.0 1.9 0.736
.1 155.5 67.1 0.759
102.1 83.4 0.680
.0 112.6 108.4 0.809
14.5 4.6 0.216
1.0 0.2 0.148
hite blood cells.
Figure 1. Kaplan-Meier curve of the time to defervescence in
the patients with noncomplicated scrub typhus. Twenty-five
cases received intravenous minocycline and 22 cases received
oral doxycycline. The markers represented the patients without
response to initial tetracycline antibiotics.
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In vitro, O tsutsugamushi is susceptible to doxycycline and
minocycline.15 Presently, although intravenous minocycline
required less time to achieve peak concentration, the
response rate and the time to defervescence in patients
with noncomplicated scrub typhus treated by intravenous
minocycline were not different from patients treated with
oral doxycycline. The reported minimum inhibitory conc-
entration of doxycycline is 0.15e0.31 mg/mL,15,16 which is
much lower than the peak level of 100 mg oral doxycycline
(1.7 mg/mL). Oral doxycycline is convenient to use and does
not pose a risk for complications caused by insertion of
a venous catheter. In addition, oral doxycycline is much
cheaper than intravenous minocycline. Except when a pa-
tient is unable to take oral medicine, intravenous minocy-
cline is not superior to oral doxycycline for noncomplicated
scrub typhus.
APACHE II score is considered as an index of severity of
infectious illness. Higher APACHE II score has been linked to
higher mortality for scrub typhus in some studies.17,18
Longer time to defervescence was found in a study inTable 2 Hazard ratios of all probable confounding factors fo
models
Probable variables
Initial antibiotics (oral doxycycline vs. intravenous minocycline)
APACHE II scores (points)
Duration of symptoms before use of tetracycline antibiotics (d)
Timing of starting tetracycline antibiotics after admission (d)
Diabetes mellitus
a p< 0.05.
APACHEZ Acute Physiology and Chronic Health Evaluation.which patients complicated with other conditions were
included.19 In our study, patients having mild illness scrub
typhus were included. Most of them had neither an
underlying disease nor high APACHE II scores. Although the
patients had noncomplicated scrub typhus, the level of
APACHE II score reflected the time to defervescence.
Prolonged hospitalization is associated with timing of
tetracycline antibiotic therapy after admission. Because
nearly all cases responding to oral doxycycline or intrave-
nous minocycline became afebrile within 3 days, it was
reasonable to suppose that delayed initiation of tetracy-
cline antibiotics after admission could prolong hospitaliza-
tion. In another study, patients with rickettsioses had
delayed defervescence despite doxycycline treatment
when they had jaundice, absence of headache, or relative
bradycardia.20 Jaundice was not evident in the present set
of patients. Relative bradycardia was not proven to be
related to prolonged hospitalization in our study, which
might be attributable to the occurrence of mild scrub
typhus in our patients. Some patients without headache did
not have delayed defervescence or prolonged hospitaliza-
tion in our study. Headache is an important clue to diagnose
scrub typhus and absence of headache may delay correct
diagnosis. But eastern Taiwan (where our hospital is
located) is an endemic area of scrub typhus. Accordingly,
scrub typhus is the first differential diagnosis for patients
with fever of unknown cause. Treatment with tetracycline
antibiotics or quinolones is typically used in febrile patients
with or without headache. Therefore, delayed deferves-
cence or prolonged hospitalization was not noted in our
patients without headache.
In a prior study, a longer duration between disease onset
and tetracycline treatment was not related to delayed
defervescence,20 as was noted in our study that included
patients with noncomplicated scrub typhus. However,
delaying adequate treatment for scrub typhus has been
associated with severe complications, including acute
respiratory failure or acute renal failure, which prolong
hospitalization.17 In our study, patients with severe com-
plications of scrub typhus had been excluded. Delayed
defervescence may not occur in patients with noncompli-
cated scrub typhus. In addition, information concerning the
duration between disease onset to treatment was collected
from the declaration of the patients or their family
members. It is likely that the degree of illness severity
varied individually, and the recall information did not
reflect the correct duration of illness. Factors other than
duration of illness probably will be associated with the
severity of disease.r the time to defervescence by multivariate Cox regression
Hazard ratio 95% Confidence interval p
1.271 0.671e2.407 0.462
0.868 0.774e0.973 0.016a
0.983 0.900e1.073 0.695
1.174 0.941e1.465 1.174
0.153 0.019e1.262 0.081
Table 3 Analysis of risk factors for prolonged hospitalization in the patients with noncomplicated scrub typhusb
Variable Duration of hospitalization p
 7 days (nZ 36) > 7 days (nZ 11)
Age, yr 52.3 16.6 52.1 22.9 0.980
No. of men/women 18/18 7/4 0.654
Duration of symptoms before use of tetracycline antibiotics, d 7.4 4.0 7.6 3.9 0.889
Timing of starting tetracycline antibiotics after admission, d 1.3 0.5 4.4 2.3 <0.001a
Time to defervescence, hr 26.4 20.6 48.0 55.1 0.055
Underlying disease
Hypertension 3 (8) 3 (27) 0.131
Chronic hepatitis B or C 3 (8) 1 (9) 1.000
Diabetes mellitus 0 (0) 2 (18) 0.051
No underlying disease 28 (78) 6 (55) 0.246
Clinical symptoms and signs
Eschar 24 (67) 6 (55) 0.493
Skin rash 9 (25) 3 (27) 1.000
Headache 21 (58) 4 (36) 0.351
Relative bradycardia 28 (78) 6 (55) 0.246
Laboratory
Platelet,103/mL 151.1 81.0 187.6 94.7 0.214
Hemoglobin, g/dL 12.8 1.8 13.2 0.8 0.536
White cell count,103/mL 7.2 2.5 7.6 3.5 0.611
Aspartate aminotransferase, IU/L 115.2 95.7 89.7 59.9 0.411
Alanine aminotransferase, IU/L 97.9 71.5 96.8 58.0 0.965
APACHE II score, points 5.2 3.2 7.2 3.2 0.077
Treatment
Oral doxycycline 18 (50) 4 (36) 0.654
a p< 0.05.
b Data are presented as mean  standard deviation or n (%).
APACHEZ Acute Physiology and Chronic Health Evaluation.
Therapy for noncomplicated scrub typhus 37Because of the retrospective design of this study, we did
not control all confounding variables to affect the time to
defervescence. We did not have data concerning pathogen
strains and could not control the criteria for selection of
therapeutic regimens. Previous reports showedanoteworthy
proportion of patientswith probable coinfections,21,22 which
were not presently ascertained. Because the moment when
the patient’s vital sign was checked was selected for the
calculation of the time to defervescence, different intervals
used in checking vital signs may have resulted in an error. In
addition, the number of patients was small, limiting the
interpretative power of the results.
Despite these limitations, the present study does
provide information that oral doxycycline is not inferior to
intravenous minocycline for the treatment of noncompli-
cated scrub typhus. Oral doxycycline is cheaper and more
convenient to use and lacks the risk for complications
caused by insertion of a venous catheter. Thus, oral doxy-
cycline should be considered as the initial treatment for
noncomplicated scrub typhus.
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